EOLS

Evolus, Inc. · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Major
Website evolus.com
Employees(FY) 246
ISIN US30052C1071

Performance

+2.94%

-8.69%

-39.77%

-12.56%

-4.8%

YTD

-15.79%

Profile

Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It serves self-pay aesthetic healthcare market. Evolus, Inc. was incorporated in 2012 and is headquartered in Newport Beach, California.

Advanced Technical Analysis

Technical Analysis of EOLS 2025-01-17

The stock indicators reflect a bearish sentiment overall, with the Moving Average Score at 23 indicating strong bearish momentum, while the Technical Score of 36 further supports this outlook. The Oscillators Score of 50 suggests a neutral position, but the prevailing bearish signals from the other indicators imply caution for potential investors.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of EOLS

Stock Rank

Recent News & Updates

2025-01-17 16:05
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)(Business Wire)
2025-01-17 03:05
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)(Businesswire)
2024-12-20 05:39
Evolus, Inc.'s (NASDAQ:EOLS) Path To Profitability(Simply Wall St.)
2024-12-13 16:05
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)(Business Wire)
2024-12-13 03:05
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)(Businesswire)
2024-11-18 09:55
Here's Why Evolus (EOLS) Could be Great Choice for a Bottom Fisher(Zacks)
2024-11-14 09:35
Down -29.8% in 4 Weeks, Here's Why You Should You Buy the Dip in Evolus (EOLS)(Zacks)
2024-11-09 09:23
Earnings Update: Evolus, Inc. (NASDAQ:EOLS) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts(Simply Wall St.)
2024-11-08 06:10
Evolus Third Quarter 2024 Earnings: Misses Expectations(Simply Wall St.)
2024-11-07 06:00
Evolus Inc (EOLS) Q3 2024 Earnings Call Highlights: Revenue Surge Amid Market Challenges(GuruFocus.com)
2024-11-06 18:25
Evolus, Inc. (EOLS) Reports Q3 Loss, Misses Revenue Estimates(Zacks)
2024-11-06 16:05
Evolus Reports Third Quarter 2024 Results(Business Wire)
2024-11-06 03:05
Evolus Reports Third Quarter 2024 Results(Businesswire)
2024-11-01 08:00
Evolus to Participate in Stifel 2024 Healthcare Conference(Business Wire)
2024-10-31 20:00
Evolus to Participate in Stifel 2024 Healthcare Conference(Businesswire)
2024-10-31 15:08
Evolus Gains EU Approval for Estyme Hyaluronic Acid Fillers(MT Newswires)
2024-10-31 14:02
Evolus Announces EU Approval of Estyme® Injectable Hyaluronic Acid Gels Under New Medical Device Regulation(Business Wire)
2024-10-31 10:02
Insulet (PODD) Earnings Expected to Grow: Should You Buy?(Zacks)
2024-10-31 02:02
Evolus Announces EU Approval of Estyme Injectable Hyaluronic Acid Gels Under New Medical Device Regulation(Businesswire)
2024-10-30 10:01
Will Evolus, Inc. (EOLS) Report Negative Earnings Next Week? What You Should Know(Zacks)
2024-10-29 08:00
Evolus Rewards™ Patient Loyalty Program Surpasses 1 Million Enrolled Consumers(Business Wire)
2024-10-28 20:00
Evolus Rewards Patient Loyalty Program Surpasses 1 Million Enrolled Consumers(Businesswire)
2024-10-23 08:00
Evolus to Report Third Quarter Financial Results on November 6, 2024(Business Wire)
2024-10-22 20:00
Evolus to Report Third Quarter Financial Results on November 6, 2024(Businesswire)
2024-10-11 22:53
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)(Business Wire)
2024-10-11 10:53
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)(Businesswire)
2024-10-10 11:29
Evolus' (NASDAQ:EOLS) investors will be pleased with their solid 119% return over the last three years(Simply Wall St.)
2024-10-09 15:36
Evolus Inc (EOLS) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Advancements(GuruFocus.com)
2024-09-27 21:00
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)(Business Wire)
2024-09-27 09:00
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)(Businesswire)

Page 1 of 9

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.